MARKET

CABA

CABA

Cabaletta Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.91
+0.58
+4.05%
Opening 10:58 02/25 EST
OPEN
14.67
PREV CLOSE
14.33
HIGH
15.36
LOW
14.42
VOLUME
9.64K
TURNOVER
--
52 WEEK HIGH
19.63
52 WEEK LOW
7.56
MARKET CAP
336.26M
P/E (TTM)
-17.9142
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CABA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CABA stock price target is 22.00 with a high estimate of 25.00 and a low estimate of 19.00.

EPS

CABA News

More
  • Cabaletta Bio to Present at the Cowen and Company 40th Annual Health Care Conference
  • GlobeNewswire · 5d ago
  • The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance
  • Benzinga · 01/30 14:26
  • The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance
  • Benzinga · 01/30 14:26
  • Cabaletta Bio Reports FDA Granted DSG3-CAART Orphan Drug Designation For Treatment Of Pemphigus Vulgaris
  • Benzinga · 01/29 13:06

Industry

Biotechnology & Medical Research
-1.95%
Pharmaceuticals & Medical Research
-1.18%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About CABA

Cabaletta Bio Inc. is a clinical stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.
More

Webull offers kinds of Cabaletta Bio Inc stock information, including NASDAQ:CABA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CABA stock news, and many more online research tools to help you make informed decisions.